Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Next Previous
Trial Profile

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms Dal-GenE
  • Sponsors DalCor Pharmaceuticals

Most Recent Events

  • 21 Jul 2022 According to a DalCor Pharmaceuticals media release, results from this trial were published in European Heart Journal.
  • 21 Jul 2022 Results published in the DalCor Pharmaceuticals Media Release.
  • 21 Jul 2022 Primary endpoint (Composite of Major Cardiovascular Adverse Events (MACE), death, MI and stroke in ITT population) has not been met, according to a DalCor Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top